PALISADE BIO INC (PALI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.09+1.95%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PALI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 231.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PALI — earnings in line
Dated 2026-08-10
of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Why it matters: Positive data from the Phase 1b trials can boost confidence in PALI-2108's potential. This could attract more investment.
Supportive ifThe company reports positive results from the Phase 1b trials for PALI-2108.
Worry ifThe data from the Phase 1b trials is disappointing or shows no significant results.
Why it matters: Higher expenses may show poor cost management. This can affect future funding and operations.
Worry ifOperating expenses are over $10M for Q2 2026. This shows costs are going up.
Less concerning ifOperating expenses are under $10M. This shows better control of costs.
Why it matters: Keeping a strong financial position is key. It helps fund important clinical milestones.
Watch forCash and cash equivalents remain above $120 million through the end of 2026.
Also watch forCash and cash equivalents fall below $100 million by the end of 2026.
Why it matters: New directors can improve governance. They can also bring new ideas to the company.
Supportive ifNew director appointments were announced for the Board. This improves governance.
Worry ifNo new appointments were made. This shows no progress in improving governance.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$294 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $903 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,040 loss on $10,000 · 40.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting the Phase 2 trial is a key step in proving PALI-2108's effectiveness. This could lead to significant value for the company.
Supportive ifThe Phase 2 trial for Ulcerative Colitis begins as planned in Q3 2026.
Worry ifThe trial initiation is delayed beyond Q3 2026.
Why it matters: Submitting the IND is crucial for advancing PALI-2108 in Crohn's Disease. It shows progress in the drug's development.
Supportive ifThe IND submission for the Phase 2 trial in Crohn's Disease occurs in 2H 2026.
Worry ifThe IND submission is postponed beyond 2H 2026.
Why it matters: Enrollment shows progress in testing PALI-2108 for ulcerative colitis. This trial is important for future results.
Supportive ifThe first patient is enrolled in the Phase 2 ASCENTRA-UC trial of PALI-2108.
Worry ifNo patients are enrolled by the end of 2026.
Why it matters: Submitting the IND is crucial for starting the trial for Crohn's disease. This step is vital for PALI-2108's development.
Supportive ifThe IND application for the Phase 2 ASCENTRA-CD trial is submitted to the FDA.
Worry ifThe IND submission is delayed beyond the second half of 2026.
Why it matters: Updates on cash reserves will indicate if the company can fund its clinical trials. This is important for investor confidence.
Worry ifCash and cash equivalents remain above $120 million.
Less concerning ifCash reserves drop below $100 million. This raises concerns about funding.
Why it matters: Results will show how well PALI-2108 works for ulcerative colitis. This data is key for future funding.
Supportive ifPrimary results from the ASCENTRA-UC trial will come in the second half of 2027.
Worry ifResults show they are not very effective. They are also late beyond the expected time.